Clinical Trials Logo

Nash clinical trials

View clinical trials related to Nash.

Filter by:

NCT ID: NCT04006145 Completed - NAFLD Clinical Trials

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Start date: June 6, 2019
Phase: Phase 2
Study type: Interventional

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)

NCT ID: NCT03980912 Withdrawn - NAFLD Clinical Trials

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

Start date: September 1, 2019
Phase:
Study type: Observational

This study is to assess the diagnostic performance of the LiverFASt Test for assessing fibrosis staging scores compared to the assessment of liver tissue pathology from liver biopsy.

NCT ID: NCT03207425 Completed - NASH Clinical Trials

A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Start date: June 14, 2017
Phase: Phase 1
Study type: Interventional

This is a study to characterize the pharmacokinetics as well as safety and tolerability of a single oral dose of EDP-305 in subjects with mild and moderate hepatic impairment compared to matched healthy subjects.

NCT ID: NCT03187496 Completed - NASH Clinical Trials

Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.

Start date: May 11, 2017
Phase: Phase 1
Study type: Interventional

A non-randomized, multiple-dose, open-label, single sequence study to evaluate effect of concomitant administration of EDP-305 on the pharmacokinetics and safety of midazolam, caffeine, and rosuvastatin in healthy human volunteers.

NCT ID: NCT02923154 Completed - NASH Clinical Trials

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

Start date: September 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.

NCT ID: NCT01269320 Withdrawn - Nash Clinical Trials

Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease

Start date: January 2012
Phase: Phase 4
Study type: Interventional

This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome. Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions. Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.